2019
Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database
Mahal A, Butler S, Franco I, Muralidhar V, Larios D, Pike L, Zhao S, Sanford N, Dess R, Feng F, D’Amico A, Spratt D, Yu J, Nguyen P, Rebbeck T, Mahal B. Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer 2019, 125: 3338-3346. PMID: 31251398, DOI: 10.1002/cncr.32332.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerPositive biopsy coresShort-term outcomesBiopsy coresProstate cancerManagement of low-risk prostate cancerOlder patientsProstate cancer-specific mortality ratesConservative managementProstate cancer-specific mortalityCancer-specific mortality ratesActive surveillance/watchful waitingRate of conservative managementOlder menCancer-specific mortalityShort-term safetyQuality-of-life implicationsDefinitive treatmentYounger patientsOverall mortalityPatientsMortality rateProstateNational databaseCancer
2017
Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance
Mahal A, Mahal B, Nguyen P, Yu J. Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. Cancer 2017, 124: 752-759. PMID: 29084350, DOI: 10.1002/cncr.31106.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityMetastatic diseaseCancer-specific mortalityProstate cancer outcomesOutcomes of patientsMedicaid insuranceEnd Results ProgramReceipt of therapyStage of diseaseAfrican American patientsInsurance statusPrivately insured cohortDefinitive treatmentProstate cancerLocalized CaPResults ProgramPrivate insuranceCAP outcomesCancer outcomesAmerican patientsPatientsProstateRacial disparitiesAssociated with raceAssociated with racial disparitiesRacial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Yu J, Feng F, Kim S, Beard C, Martin N, Trinh Q, Nguyen P. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Annals Of Oncology 2017, 28: 1098-1104. PMID: 28453693, DOI: 10.1093/annonc/mdx041.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityProstate-specific antigenUnited States Preventive Services Task ForceRisk of prostate cancer-specific mortalityProstate cancer outcomesBlack raceMetastatic diseaseCancer outcomesProstate-specific antigen screeningRate of metastatic diseasePSA screening guidelinesCancer-specific mortalityRisk of poor outcomesStage of presentationPreventive Services Task ForceScreening-eligible ageMultivariate logistic regressionEligible populationNon-black menSEER databaseProstate cancerBlack menScreening guidelinesPoor outcomeRisk regressionRacial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Beard C, Martin N, Feng F, Kim S, Yu J, Trinh Q, Nguyen P. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Journal Of Clinical Oncology 2017, 35: 18-18. DOI: 10.1200/jco.2017.35.6_suppl.18.Peer-Reviewed Original ResearchProstate cancer-specific mortalityProstate-specific antigenRisk of prostate cancer-specific mortalityProstate-specific antigen screeningProstate cancer outcomesUnited States Preventive Services Task ForceBlack raceMetastatic diseaseCancer outcomesRate of metastatic diseaseCancer-specific mortalityStage of presentationRisk of poor outcomesPreventive Services Task ForceScreening-eligible ageMultivariate logistic regressionEligible populationNon-black menProstate-specificSEER databaseProstate cancerBlack menPoor outcomeRisk regressionBlack patientsOutcomes for men under 65 with high-risk prostate cancer with Medicaid versus private insurance.
Mahal A, Mahal B, Nguyen P, Yu J. Outcomes for men under 65 with high-risk prostate cancer with Medicaid versus private insurance. Journal Of Clinical Oncology 2017, 35: 198-198. DOI: 10.1200/jco.2017.35.6_suppl.198.Peer-Reviewed Original ResearchProstate cancer-specific mortalityHigh-risk prostate cancerProstate cancerTreatment of high-risk prostate cancerInsurance statusCompeting-risks regression modelsHigh-risk CaPPrivately insured menGray's competing-risks regression modelHigh-risk diseaseCancer-specific mortalityEnd Results ProgramMultivariate logistic regressionMetastatic diseaseNon-black menResults ProgramPrivate insuranceInsured menAfrican American menLogistic regressionMetSOutcomesCancerMenMore-than-additive effect
2015
Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?
Mahal B, Muralidhar V, Chen Y, Choueiri T, Hoffman K, Hu J, Sweeney C, Yu J, Feng F, Trinh Q, Nguyen P. Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? BJU International 2015, 118: 95-101. PMID: 26207642, DOI: 10.1111/bju.13239.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityGleason score 5Risk of prostate cancer-specific mortalityGleason score 4Prostate cancerScore 5Increased risk of PCSMGray competing risk regression analysisProstate cancer-specific mortality outcomesProstate cancer-specific mortality ratesScore 4Competing risk regression analysisGleason score 3Gleason score 8Gleason score 9Primary Gleason patternReference group of patientsCancer-specific mortalityAggressive treatment strategiesGroup of patientsRisk regression analysisHighest-risk patientsGleason 4Gleason scoreGleason pattern
2012
A Decision Analysis to Assess the Value of Prostate Cancer Screening: A Shift in Focus From Prostate Cancer-specific Mortality to Distant Metastasis-free Survival
Dosoretz A, Lester-Coll N, Yu J. A Decision Analysis to Assess the Value of Prostate Cancer Screening: A Shift in Focus From Prostate Cancer-specific Mortality to Distant Metastasis-free Survival. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s57. DOI: 10.1016/j.ijrobp.2012.07.355.Peer-Reviewed Original Research